Monday, November 11, 2019
- 9:00AM-11:00AM
-
Abstract Number: 1688
Glucocorticoids Plus Rituximab versus Glucocorticoids Plus Placebo in Non-infectious Active Mixed Cryoglobulinemia Vasculitis: Results of a Placebo-Controlled Randomized Trial
Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides- 9:00AM-11:00AM
-
Abstract Number: 1446
Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany
RA – Treatments Poster II: Established Treatments- 9:00AM-11:00AM
-
Abstract Number: 1477
Golimumab Improves Direct Costs of Healthcare Utilization and Indirect Costs Within Patients with RA, PsA, and as – Analysis of a Non-Interventional Study in Germany
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1087
Golimumab Improves Work Productivity and Activity and Quality of Life in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Final Results from a Non-Interventional Study in Germany (GO-ART)
Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease- 9:00AM-11:00AM
-
Abstract Number: 1499
Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1183
Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study
Imaging Of Rheumatic Diseases Poster II- 9:00AM-11:00AM
-
Abstract Number: 1117
Government Subsidization of Biologic Therapy for Inflammatory Arthritis in a Co-Funded Healthcare Model: A Singapore Experience
Health Services Research Poster II – ACR/ARP- 9:00AM-11:00AM
-
Abstract Number: 1668
Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Registry
Vasculitis – ANCA-Associated Poster II- 9:00AM-11:00AM
-
Abstract Number: 1494
Guselkumab Was More Effective Than Secukinumab in Patients with Plaque Psoriasis and the Subset of Patients with Self-Reported Psoriatic Arthritis in a Randomized, Double-blind, Head-to-head Comparison Study over 1 Year
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1712
Head and Neck Involvement of IgA Vasculitis: A Case-Control Study
Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides- 9:00AM-11:00AM
-
Abstract Number: 1125
Health Care Resource Utilization and Costs in Patients with Juvenile Idiopathic Arthritis Treated with Abatacept and Other Targeted Disease Modifying Anti-rheumatic Drugs
Health Services Research Poster II – ACR/ARP- 9:00AM-11:00AM
-
Abstract Number: 1756
Health-related Social Media Use by Parents of Children with Rheumatic Diseases
Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma- 9:00AM-11:00AM
-
Abstract Number: 1656
Health-Related Quality of Life in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Impact of Lung Function on Patient-Reported Outcomes in a Randomized Phase III Trial
Systemic Sclerosis & Related Disorders – Clinical Poster II- 9:00AM-11:00AM
-
Abstract Number: 1470
Health-Related Quality of Life in Primary Sjogren’s Syndrome: Insights from Using PROMIS and Comparison to ESSPRI